Latest Treatments of Parkinson's Disease Stories
WALTHAM, Mass., May 12 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that while levodopa remains the gold standard for Parkinson's disease treatment, physicians say they will increasingly use other agents to delay the need for levodopa.
RIDGEFIELD, Conn., March 23 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc., today announced that the U.S.
RIDGEFIELD, Conn., Feb. 22 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc., today announced that the U.S.
WALTHAM, Mass., Jan.
NEW YORK, Nov. 30 /PRNewswire-USNewswire/ -- The Michael J. Fox Foundation for Parkinson's Research (MJFF) today announced $1.5 million in total awards to six research teams working to develop potentially disease-modifying therapies for Parkinson's disease.
A Michigan hospital is embarking on a research study for advanced Parkinson's disease using a state-of-the-art treatment called gene transfer.
WEST BLOOMFIELD, Mich., Oct. 6 /PRNewswire/ -- Henry Ford West Bloomfield Hospital is embarking on a research study for advanced Parkinson's disease using a state-of-the-art treatment called gene transfer.
Rush University Medical Center is participating in a large-scale, multi-center clinical trial in the U.S. and Canada to determine whether a vitamin-like substance, in high doses, can slow the progression of Parkinson's disease, a neurodegenerative disorder that affects about one million people in the United States.
Scientists in the Academy of Finland's Neuroscience Research Programme have reported promising new results with potential implications for the treatment of Parkinson's disease.
Data indicated comparable efficacy and safety for extended release and immediate release formulations of pramipexole SEATTLE, April 29 /PRNewswire/ -- New findings from two double-blind studies investigating the efficacy, safety and tolerability of pramipexole dihydrochloride tablets in an extended release, once-daily formulation, for the treatment of Parkinson's disease (PD), are being presented today at the American Academy of Neurology (AAN) 61st Annual Meeting in Seattle. The first...